Abstracts tagged "chemokines"

Abstract Number: 932 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Kentaro Torii ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 997 • 2019 ACR/ARP Annual Meeting
Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis
Maria de la luz Garcia-Hernandez¹, Javier Rangel-Moreno ², Benjamin Korman ², Ananta Paine ¹, Nelson Huertas ³ and Christopher T. Ritchlin ³, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³University of Rochester, Rochester, NY
Background/Purpose: DC-STAMP is a transmembrane protein involved in the fusion of mononuclear osteoclasts and essential for the formation of fully functional multinucleated osteoclasts (OCs). Recently…
Abstract Number: 1047 • 2019 ACR/ARP Annual Meeting
CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage
Vasiliki Kalliopi Bournia¹, Markos Patsouras ², Nikolaos Vlachoyiannis ³, Athanasios Tzioufas ⁴, Petros Sfikakis ⁵ and Panagiotis Vlachoyiannopoulos ⁶, ¹1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece, Athens, ³1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, ⁴Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁶University General Hospital of Athens “Laiko”, Athens, Greece
Background/Purpose: Recent findings have implicated CXCL4 in the pathogenesis of systemic sclerosis (SSc), while also indicating a potential role of this chemokine as a biomarker…
Abstract Number: 1764 • 2019 ACR/ARP Annual Meeting
CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion
Sadiq Umar¹, Katrien Raemdonck ¹, Karol Palasiewicz ¹, Michael Volin ², Shiva Arami ¹, Suncica Volkov ¹, Nadera Sweiss ¹, M Amin ³ and Shiva shahrara ¹, ¹University of Illinois at chicago, Chicago, IL, ²Department of Microbiology & Immunology, Midwestern University, Downer Grove, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Background/Purpose: CCL25 and its receptor CCR9 have been detected in the inflamed joint; however their role is undefined in rheumatoid arthritis (RA). Hence studies…
Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
Gian Marco Moneta¹, Ivan Caiello¹, Lucilla Rava'², Silvia Rosina³, Luisa Bracci Laudiero^1,4, Angelo Ravelli^3,5, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Institute of Translational Pharmacology, CNR, Roma, Italy, ⁵Rheumatology, Giannina Gaslini Institute, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
Abstract Number: 92 • 2018 ACR/ARHP Annual Meeting
Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
Dayvia Russell¹, Margaret Markiewicz², Xian Zhang² and Jim C. Oates³, ¹Research Service, Ralph H. Johnson VA Medical Center, Charleston, SC, ²Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Medical Service, Ralph H. Johnson VA Medical Center, Charleston, SC
Title: Lupus Nephritis Serum Induces Neutrophil Chemotaxis towards Glomerular Endothelial Cells In Vitro Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with…
Abstract Number: 840 • 2018 ACR/ARHP Annual Meeting
The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis
Katrien Van Raemdonck^1,2, Karol Palasiewicz^1,2, Sadiq Umar^1,2 and Shiva Shahrara², ¹Jesse Brown VA Medical Center, Chicago, IL, ²Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: The synovial tissue of rheumatoid arthritis (RA) patients exhibits abundant expression of CCL21, produced excessively by RA fibroblasts and macrophages. While CCR7 mediates CCL21-driven…
Abstract Number: 983 • 2018 ACR/ARHP Annual Meeting
A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Anders Mellemkjær³, Morten Aagaard Nielsen⁴, Line Dam Heftdal², Marie Iversen³, Peter Schafer⁵ and Bent Deleuran², ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: Targeting intracellular pathways with oral small molecules is an attractive therapeutic approach for treating immune mediated inflammatory diseases. The mitogen-activated protein kinase (MAPK) pathway…
Abstract Number: 987 • 2018 ACR/ARHP Annual Meeting
CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis
Kuninobu Wakabayashi, Takeo Isozaki, Shinichiro Nishimi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is produced by a variety of cell types. By interacting with C-C chemokine receptor…
Abstract Number: 995 • 2018 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice
Kana Hoshino-Negishi¹, Masayoshi Ohkuro², Tomoya Nakatani¹, Wataru Ikeda¹, Yoshikazu Kuboi¹, Naoto Ishii¹, Nobuyuki Yasuda¹ and Toshio Imai³, ¹KAN Research Institute, Inc., Kobe, Japan, ²Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki, Japan, ³President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
Abstract Number: 1001 • 2018 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model
Wataru Ikeda¹, Kana Hoshino-Negishi¹, Eri Fusaoka-Nishioka¹, Tomoya Nakatani¹, Yoshikazu Kuboi¹, Naoto Ishii¹, Nobuyuki Yasuda¹ and Toshio Imai², ¹KAN Research Institute, Inc., Kobe, Japan, ²President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
Abstract Number: 1417 • 2018 ACR/ARHP Annual Meeting
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
Giulia Marucci¹, Ivan Caiello², Manuela Pardeo¹, Virginia Messia¹, Giusi Prencipe¹, Antonia Pascarella¹, Fabrizio De Benedetti³ and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Increased ferritin is considered biomarker highly suggestive of primary and secondary HLH and it is one of the HLH-2004 diagnostic and MAS guidelines (1,2),…
Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting
Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Peter M. Maloley¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Michael J. Duryee³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…
Abstract Number: 1379 • 2017 ACR/ARHP Annual Meeting
Epithelial Neutrophil-Activating Peptide 78/C-X-C Motif Chemokine 5 in the Insulin Resistance of Patients with Rheumatoid Arthritis
Hiurma Sanchez-Perez¹, Beatriz-Segura Tejera², De Vera-González AM³, Alejandra González Delgado⁴, Jose M Olmos⁵, José Luis Hernandez⁶, Begoña Ubilla⁷, Raquel Lopez-Mejías⁸, Miguel Angel González-Gay⁹ and Ivan Ferraz-Amaro¹⁰, ¹Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ²Rheumatology section, Hospital Germans Trias i Pujol, Badalona, Spain, ³Central Laboratory Division, University Hospital of Canary Islands, Tenerife, Spain, ⁴Central Laboratory Division. Hospital Universitario de Canarias, Tenerife, Spain., Tenerife, Spain, ⁵Division of Internal Medicine. Hospital Universitario Marqués de Valdecilla, IDIVAL.Universidad de Cantabria. RETICEF, Santander, Spain, ⁶Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁷Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁸Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Johannesburg, South Africa, ¹⁰Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: It is known that the chemokine molecule CXCL5 (C-X-C motif chemokine 5 or epithelial neutrophil activating peptide 78 -ENA78-) is a link between obesity,…
Abstract Number: 1907 • 2017 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Nobuyuki Yasuda⁵, Fumitoshi Tago⁶, Makoto Kawakubo⁶, Yasumi Kitahara⁶, Seiichiro Hojo⁶, Tetsu Kawano⁷ and Toshio Imai⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁵KAN Research Institute, Inc., Tokyo, Japan, ⁶Eisai Co., Ltd., Tokyo, Japan, ⁷KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We previously presented the interim results…

« Previous Page
1
…
3
4
5
6
7
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].